Ekso Bionics Accepted into NVIDIA Connect Program
Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms
SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ('Ekso Bionics' or the 'Company'), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic initiative to build a proprietary foundation model for human motion, and to help develop and integrate related new artificial intelligence ('AI') capabilities across its portfolio of Enterprise Health and Personal Health devices.
NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA's advanced development kits, GPU platforms, and global ecosystem, helping facilitate the program members' ability to deliver next-generation solutions in AI and high-performance computing.
'We are privileged to join a select group of medical device innovators in the NVIDIA Connect program,' said Scott Davis, Chief Executive Officer of Ekso Bionics. 'While our advanced exoskeleton technology platforms are already state-of-the-art, in some ways we are only just approaching the starting line as we work to build and leverage what we believe will be the industry's first known foundation model for human motion in physical rehabilitation. We are excited for this journey with NVIDIA Connect and look forward to updating all of our stakeholders as we progress.'
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol 'EKSO.' For more information, visit: www.eksobionics.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company's industry, growth and strategy, including the Company's plan to build a proprietary model for human motion and the expected benefits of AI capabilities and being a part of the NVIDIA Connect program. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to realize the benefits of the NVIDIA Connect program or successfully complete the building of a proprietary model for human motion, the Company's inability develop and integrate related new AI capabilities across its portfolio, the Company's inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company's technology, the Company's inability to successfully collaborate with its network of existing neuro-rehabilitation facilities, physicians, and DMEs in seeking CMS reimbursements, the Company's inability to obtain future reimbursements from CMS in a timely manner and at the expected reimbursement levels, the Company's ability to raise funds to operate and grow its business, the Company's inability to obtain insurance coverage beyond CMS, the Company's inability to obtain additional indications of use for its devices, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing efforts or of partners to market the Company's products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company's supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. To learn more about Ekso Bionics please visit the Company's website at www.eksobionics.com or refer to the Company's X page, formerly Twitter, at @EksoBionics. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Bank of America Securities Raised the Firm's PT on Shopify Inc (SHOP), Kept a Buy Rating
Shopify Inc. (NASDAQ:SHOP) is one of the Best Performing Canadian Stocks So Far in 2025. On August 8, Bradley Sills from Bank of America Securities raised the firm's price target on Shopify Inc. (NASDAQ:SHOP) from $110 to $185, while maintaining a Buy rating on the stock. The analyst noted that the company's key growth initiatives are showing significant results. The company, in its latest fiscal second quarter 2025 earnings release, exceeded revenue and EPS estimates. The company posted $2.68 billion in revenue, up 31% year-over-year and ahead of expectations by $132.64 million. The EPS of $0.35 also surpassed estimates by $0.06. An enthusiastic customer completing a purchase and receiving an order confirmation via one of the companies online sales channels. The analyst noted that the company's merchant solutions contributed significantly to revenue growth, and the company is also winning new enterprise clients, which is good for its long-term growth. Shopify Inc. (NASDAQ:SHOP) is a global commerce company that provides tools and software for businesses to sell products online, in stores, and through social media or marketplaces. While we acknowledge the potential of SHOP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
HSBC lowers Cisco to Hold on valuation, slowing business momentum
-- HSBC on Friday downgraded Cisco Systems Inc (NASDAQ:CSCO) to Hold from Buy on elevated valuation and slowing business momentum, and cut its price target to $69 from $73. The bank also lowered its adjusted earnings per share (EPS) estimates for fiscal years 2026 (FY26) to 2028 by around 7% to 14% to reflect a weaker-than-expected outlook. Cisco's fourth-quarter fiscal 2025 results and fiscal 2026 guidance were in line with consensus but came in below HSBC's estimates. Revenue rose 7.6% year-on-year to $14.67 billion, matching both HSBC and consensus expectations. Non-GAAP operating margin was 34.3%, up 1.73 percentage points from a year earlier, but below HSBC's forecast of 35.3% and in line with consensus. Non-GAAP EPS increased 13.8% to $0.99, also in line with estimates. The company's networking segment showed improvement, with revenue growth accelerating from a 23.5% decline in the first quarter to a 12.2% increase in the fourth. However, HSBC analysts note that Cisco's fiscal 2026 revenue guidance of 5% growth, combined with slowing growth in remaining performance obligations and backlog, suggests 'the restocking effect may be coming to an end sooner we had expected.' Although Cisco reported over $2 billion in AI infrastructure orders in fiscal 2025, the strength 'seems to be getting offset by weakness elsewhere.' In security, revenue grew 9.2% in the quarter and orders rose in the mid-single digits, with double-digit growth excluding the U.S. federal market. Still, HSBC cut its long-term revenue CAGR estimate for the segment to 8% from around 10%, saying overall growth is 'disappointing' despite good cross-selling traction from the Splunk acquisition. Cisco shares have risen 42% since August 2024, outperforming the Nasdaq by 19 percentage points, and 'appear fairly valued," analysts said. The stock trades at 17.2 times estimated 2026 adjusted earnings, in line with other slow-growth companies under the bank's coverage. The new price target is based on a 17.5 times multiple applied to HSBC's next 12-month non-GAAP EPS estimate of $3.93, down from $4.16. The target implies a 2% downside. Related articles HSBC lowers Cisco to Hold on valuation, slowing business momentum After soaring 149%, this stock is back in our AI's favor - & already +25% in July Tesla: Hype Aside, How Much Is the EV Giant Really Worth Now? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
18 minutes ago
- Forbes
Markets Flat As Inflation Data Raises Tariff Concerns Ahead Of Jackson Hole
Key Takeaways Equities are experiencing their own dog days of summer. On Thursday, the S&P 500, Nasdaq Composite and Dow Jones Industrial Average closed flat on the day. The only movers were small cap stocks, which closed down on the day by 1.3%. The big news on the day was inflation data. Thursday's Producer Price Index (PPI) came in significantly higher than expectations, and that followed a Consumer Price Index (CPI) report which had already raised at least one eyebrow for some. Year-over-year prices jumped 3.3% up from 2.4% and the monthly rate of increase, which had been flat, jumped 0.9%. What I find interesting here is the market's reaction and the expectations vis-a-vis interest rates. Initially, equity markets sold off on the news and bonds fell. However, according to the CME Fed Watch Tool, expectations for a quarter-point rate cut at the next Fed meeting still stand at over 92%. Continuing with the macroeconomic picture, the most recent data on Retail Sales was released this morning. While the headline number came in as expected at 0.3%, a much less talked about number is grabbing a lot of attention. The Import Price Index, which measures price changes of imported goods, increased by 0.4%. That number had been forecast to be up 0.1%. The reason this number matters is because of how it relates to tariffs. One of the hopes of those in support of the tariff policy was that countries would pay to access our markets. Those opposing tariffs have argued the cost of tariffs would be passed along in the form of higher prices paid by consumers. This particular data point could be a sign that countries are beginning to pass those costs to U.S. consumers. Albeit it's only one report and you cannot make any conclusions from one report; however, at the same time Chicago Fed president Austan Goolsbee noted that the combination of the higher-than-expected CPI, PPI and now Import Price Index has injected a "note of unease" into what was a "golden road" toward lowering interest rates. Next week, global economic policy makers will gather in Jackson Hole, Wyoming. This year's theme centers around labor markets, however, the meeting will cover a range of topics and interest rate policy will certainly be among them. Because of the timing of the Jackson Hole conference, the Federal Reserve won't meet until mid September, which means that although current expectations are very high for a rate cut, the Fed will have a lot more data to work with prior to making any decisions. There are some individual stocks making news in the premarket session. Shares of UnitedHealth Group are indicated higher by nearly 10% following the disclosure Warren Buffett's Berkshire Hathaway purchased more than five million shares in the company valued at $1.6 billion. Berkshire also sold twenty million shares of Apple during the quarter. According to the Wall Street Journal, that was the first time Berkshire reduced its position in Apple since last year. We also heard from Applied Materials after the close Thursday. The chipmaker reported earnings that beat expectations; however, the company lowered its guidance on an uncertain outlook, particularly with respect to China. Those shares are indicated lower by 15%. For today, I'm watching a few things. First, I'm keeping an eye on shares of Intel after President Trump suggested the government may be looking to invest in the company. This is something we saw during the housing crisis when a multitude of companies were on the brink of failure, but the idea of an investment in Intel is a bit surprising. I'm also paying attention to the meeting taking place in Alaska between Presidents Trump and Putin over the war between Russia and Ukraine. Lastly, I'm watching bonds. With the data received this week, the inflation outlook is muddy. Bonds will have the ultimate say in where interest rates head, so I'm keeping close watch on how they close the week. As always, I would stick with your investing plans and long-term objectives.
